Cidara Therapeutics, Inc. Stock

$56.42

0.48% today

Nasdaq, Jul 18, 05:18 pm CET

ISIN

US1717571079

Symbol

CDTX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Cidara Therapeutics, Inc. Stock price

$56.15

-20.45 26.70% 5Y

Nasdaq, Closing price Thu, Jul 17 2025

+3.89 7.44%

ISIN

US1717571079

Symbol

CDTX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$1.2b

Enterprise Value

$1.1b

Net debt

positive

Cash

$168.2m

Shares outstanding

12.2m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

4,139.7 | -

EV/Sales

3,579.2 | -

EV/FCF

negative

P/B

8.8

Financial Health

Equity Ratio

76.0%

Return on Equity

-104.0%

ROCE

-134.9%

ROIC

Debt/Equity

0.0

Financials (TTM | estimate)

Revenue

$300.0k | $0.0

EBITDA

$-192.6m | $-124.4m

EBIT

$-192.8m | $-145.6m

Net Income

$-183.0m | $-99.0m

Free Cash Flow

$-192.0m

Growth (TTM | estimate)

Revenue

-99.4% | -100.0%

EBITDA

-406.7% | -36.7%

EBIT

-405.4% | -59.7%

Net Income

-401.7% | 41.7%

Free Cash Flow

-931.4%

EPS

$-12.9

FCF per Share

$-15.7

Short interest

5.0%

Employees

Rev per Employee

$30.0k

As a Free StocksGuide user, you can view scores for all 7,009 stocks worldwide.

Get Started for Free Today

Cidara Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

??

13 Analysts have issued a Cidara Therapeutics, Inc. forecast:

12x Buy

92%

More details on Analyst Estimates Including Price Targets

13 Analysts have issued a Cidara Therapeutics, Inc. forecast:

Buy

92%

Hold

Analyst Estimates with Stock Price Targets

Financial data from Cidara Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	0.30 0.30	99% 99% 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	23 23	16% 16% 7,733%
- Research and Development Expense	91 91	47% 47% 30,187%
EBITDA	-193 -193	407% 407% -64,200%
- Depreciation and Amortization	0.23 0.23	64% 64% 77%
EBIT (Operating Income) EBIT	-193 -193	405% 405% -64,276%
Net Profit	-183 -183	402% 402% -60,993%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Cidara Therapeutics, Inc. Stock News

Neutral

Business Wire

●

11 days ago

Segal Trials Contributes to Breakthrough Flu Prevention Study Led by Cidara Therapeutics

MIAMI LAKES, Fla.--(BUSINESS WIRE)-- #AntiviralTreatment--Segal Trials proudly announces its participation in the successful Phase 2b NAVIGATE clinical trial conducted by Cidara Therapeutics, evaluating CD388—a novel, non-vaccine, long-acting antiviral—for the prevention of seasonal influenza. Dr. Steven Chavoustie served as the Principal Investigator for the study at Segal Trials. The NAVIGATE...

Neutral

GlobeNewsWire

●

17 days ago

Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company applying its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that the Compensation and Human Capital Committee of its Board of Directors (Compensation Committee) granted non-qualified stock option awards and restricted stock units (RSUs...

Positive

MarketBeat

●

18 days ago

Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains

The biopharmaceuticals space is notorious for sudden, sharp rallies, and for precipitous sell-offs as well. The industry is crowded with names, many of which are tiny firms working toward developing a small number of drug candidates and lacking a means of achieving profitability until one or more of those products make it to market.

More Cidara Therapeutics, Inc. News

Company Profile

Cidara Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of novel anti-infectives. Its product pipeline includes Rezafungin and Cloudbreak. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.

Head office	United States
CEO	Jeffrey Stein
Employees	38
Founded	2012
Website	www.cidara.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now